Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 7,300 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 7,300 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $54.19, for a total transaction of $395,587.00. Following the completion of the transaction, the executive vice president now directly owns 116,920 shares of the company’s stock, valued at approximately $6,335,894.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Fady Ibraham Malik also recently made the following trade(s):

• On Tuesday, October 1st, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The stock was sold at an average price of $52.10, for a total transaction of $380,330.00.
• On Tuesday, September 3rd, Fady Ibraham Malik sold 7,384 shares of Cytokinetics stock. The shares were sold at an average price of $57.01, for a total value of $420,961.84.
• On Tuesday, August 6th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The shares were sold at an average price of $53.71, for a total value of $392,083.00.
• On Tuesday, July 23rd, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The stock was sold at an average price of $57.02, for a total value of $416,246.00.

Cytokinetics Stock Down 0.2 %

Shares of CYTK opened at $55.28 on Thursday. The company has a current ratio of 10.39, a quick ratio of 10.39 and a debt-to-equity ratio of 5.93. The stock has a market capitalization of $5.80 billion, a PE ratio of -10.24 and a beta of 0.77. The firm’s 50 day moving average is $55.13 and its 200-day moving average is $57.60. Cytokinetics, Incorporated has a 12 month low of $30.37 and a 12 month high of $110.25.

Cytokinetics (NASDAQ:CYTK) last announced its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.06) by ($0.25). The business had revenue of $0.25 million during the quarter, compared to analysts’ expectations of $7.61 million. Cytokinetics’s quarterly revenue was down 71.3% on a year-over-year basis. During the same period in the previous year, the company earned ($1.34) earnings per share. Equities research analysts forecast that Cytokinetics, Incorporated will post -5.15 EPS for the current year.

Institutional Investors Weigh In On Cytokinetics

Several institutional investors and hedge funds have recently bought and sold shares of the company. State of Michigan Retirement System acquired a new position in shares of Cytokinetics in the 1st quarter valued at approximately $1,690,000. Susquehanna Fundamental Investments LLC acquired a new position in Cytokinetics during the first quarter valued at approximately $4,703,000. Entropy Technologies LP lifted its stake in Cytokinetics by 110.6% during the first quarter. Entropy Technologies LP now owns 19,433 shares of the biopharmaceutical company’s stock worth $1,362,000 after purchasing an additional 10,205 shares during the last quarter. Westfield Capital Management Co. LP acquired a new stake in shares of Cytokinetics in the 1st quarter valued at $51,277,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Cytokinetics in the 1st quarter valued at $1,249,000.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. boosted their target price on shares of Cytokinetics from $65.00 to $71.00 and gave the stock an “overweight” rating in a report on Thursday, September 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $72.00 target price on shares of Cytokinetics in a report on Tuesday, September 3rd. HC Wainwright lifted their price target on Cytokinetics from $90.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. JMP Securities restated a “market outperform” rating and issued a $78.00 price objective on shares of Cytokinetics in a research note on Wednesday, September 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Cytokinetics in a research note on Monday, September 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $83.93.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.